How PBPK Modeling Can Replace Drug-Drug Interaction Studies
Patients often take more than one drug at a time, especially elderly patients and those…
CertaraNovember 12, 2020
Certara Opens New China Office in Shanghai
Office will support rapid growth and collaboration with customers in China to accelerate biopharmaceutical R&D …
CertaraNovember 9, 2020
PBPK modeling supports approval of breakthrough cancer drug
Pharmacyclics’ (now AbbVie) Imbruvica (ibrutinib) is an anticancer drug targeting B-cell malignancies. Leveraging the US…
CertaraOctober 23, 2020
SNDS: Strengths, Limitations and Perspectives for the Largest and Richest Real-World Database in EU
In this webinar, our experts provided an overview of the SNDS and the key working…
CertaraOctober 20, 2020
